Evaluation of transplacental treatment for fetal congenital bradyarrhythmia-nationwide survey in Japan

Circulation Journal

Volumn 76, Issue 2, 2012, Pages 469-476

  Miyoshi, Takekazu ^a   Maeno, Yasuki ^b   Sago, Haruhiko ^c   Inamura, Noboru ^d   Yasukohchi, Satoshi ^e   Kawataki, Motoyoshi ^f   Horigome, Hitoshi ^e   Yoda, Hitoshi ^g   Taketazu, Mio ^h   Shozu, Makio ⁱ   Nii, Motoki ^j   Kato, Hitoshi ^c   Hayashi, Satoshi ^c   Hagiwara, Asako ^f   Omoto, Akiko ⁱ   Shimizu, Wataru ^k   Shiraishi, Isao ^a   Sakaguchi, Heima ^a   Nishimura, Kunihiro ^a   Ueda, Keiko ^a   Katsuragi, Shinji ^a   Ikeda, Tomoaki ^a   more..

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^e NAGANO CHILDREN'S HOSPITAL   (Japan)

^f KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^g UNIVERSITY OF TSUKUBA   (Japan)

^h TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

ⁱ SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^j CHIBA UNIVERSITY   (Japan)

^k SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

more..

Author keywords

Anti ro ssa antibody; Congenital atrioventricular block; Pregnancy; Steroids; Transplacental treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; DEXAMETHASONE; PREDNISOLONE; RITODRINE; RO ANTIBODY; STEROID;

ADRENAL INSUFFICIENCY; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FETUS; FETUS HEART RATE; FETUS HYDROPS; FOLLOW UP; GROWTH DISORDER; HUMAN; JAPAN; LONG QT SYNDROME; LOW BIRTH WEIGHT; MAGNETOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MATERNAL DIABETES MELLITUS; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OLIGOHYDRAMNIOS; PERINATAL DEATH; PROGNOSIS; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SINUS BRADYCARDIA; SURVIVAL RATE;

ATRIOVENTRICULAR BLOCK; BRADYCARDIA; DRUG THERAPY, COMBINATION; FEMALE; FETAL DEATH; FOLLOW-UP STUDIES; HEALTH CARE SURVEYS; HUMANS; HYDROPS FETALIS; INFANT, NEWBORN; JAPAN; KAPLAN-MEIER ESTIMATE; PREGNANCY; PRENATAL DIAGNOSIS; QUESTIONNAIRES; RISK FACTORS; STEROIDS; SYMPATHOMIMETICS;

EID: 84856258875     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1020     Document Type: Article

References (40)

1. Brucato A, Cimaz R, Caporaili R, Ramoni V, Vuyon J. Pregnancy outcome in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011; 40: 27-41.
2. Silverman ED, Buyon J, Laxer RM, Hamilton R, Bini P, Chu JL, et al. Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus. Clin Exp Immunol 1995; 100: 499-505.
3. Buyon JP, Ben-Chetrit E, Karp S, Roubey RA, Pompeo L, Reeves WH, et al. Acquired congenital heart block: Pattern of maternal antibody response to biochemically defined antigens of the SSA/Ro-SSB/ La system in neonatal lupus. J Clin Invest 1989; 84: 627-634.
4. Schmidt KG, Ulmer HE, Silverman NH, Kleinman CS, Copel JA. Perinatal outcome of fetal complete atrioventricular block: A multicenter experience. J Am Coll Cardiol 1991; 17: 1360-1366.
5. Ichikawa R, Sumitomo N, Komori A, Abe Y, Nakamura T, Fukuhara J, et al. The follow-up evaluation of electrocardiogram and arrhythmias in children with fulminant myocarditis. Circ J 2011; 75: 932-938.
6. Jaeggi ET, Laskin CA, Hamilton RM, Kingdom J, Silverman ED. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus: A prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010; 55: 2778-2784.
7. Brucato A, Grava C, Bortolati M, Ikeda K, Milanesi O, Cimaz R, et al. Congenital heart block not associated with anti-Ro/La antibodies: Comparison with anti-Ro/La-positive cases. J Rheumatol 2009; 36: 1744-1748.
8. Lopes LM, Tavares GM, Damiano AP, Lopes MA, Aiello VD, Schultz R, et al. Perinatal outcome of fetal atrioventricular block: Onehundred- sixteen cases from a single institution. Circulation 2008; 118: 1268-1275.
9. Jaeggi ET, Fouron JC, Silverman ED, Ryan G, Smallhorn J, Hornberger LK. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004; 110: 1542-1548.
10. Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune-associated congenital heart block: Demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31: 1658-1666.
11. Lee LA, Bias WB, Arnett FC Jr, Huff JC, Noris DA, Harmon C, et al. Immunogenetics of the neonatal lupus syndrome. Ann Intern Med 1983; 99: 592-596.
12. Watson RM, Lane AT, Barnett NK, Bias WB, Arnett FC, Provost TT. Neonatal lupus erythematosus: A clinical, serological and immunogenetic study with review of the literature. Medicine 1984; 63: 362-378.
13. Bierman FZ, Baxi L, Jaffe I, Driscoll J. Fetal hydrops and congenital complete heart block: Response to maternal steroid therapy. J Pediatr 1988; 112: 646-648.
14. Carreira PE, Gutierrez-Larraya F, Gomez-Reino JJ. Successful intrauterine therapy with dexamethasone for fetal myocarditis and heart block in a woman with systemic lupus erythematosus. J Rheumatol 1993; 20: 1204-1207.
15. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody associated congenital heart block. Arthritis Rheum 1999; 42: 2335-2345.
16. Groves AMM, Allan LD, Rosenthal E. Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. Circulation 1995; 92: 3394-3396.
17. Harris JP, Alexson CG, Manning JA, Thompson HO. Medical therapy for the hydropic fetus with congenital complete atrioventricular block. Am J Perinatol 1993; 10: 217-219.
18. Copel JA, Buyon JP, Kleinman CS. Successful in utero therapy of fetal heart block. Am J Obstet Gynecol 1995; 173: 1384-1390.
19. Cuneo BF, Zhao H, Strasburger JF, Ovadia M, Huhta JC, Wakai RT. Atrial and ventricular rate response and patterns of heart rate acceleration during maternal-fetal terbutaline treatment of fetal complete heart block. Am J Cardiol 2007; 100: 661-665.
20. Lazzerini PE, Capecchi PL, Laghi Pasini F. Anti-Ro/SSA antibodies and cardiac arrhythmias in the adult: Facts and hypotheses. Scand J Immunol 2010; 72: 213-222.
21. Hutter D, Silverman ED, Jaeggi ET. The benefits of transplacental treatment of Isolated congenital complete heart block associated with maternal anti-Ro/SSA antibodies: A review. Scand J Immunol 2010; 72: 235-241.
22. French NP, Hagan R, Evans SF, Godfrey M, Newnham JP. Repeated antenatal corticosteroids: Size at birth and subsequent development. Am J Obstet Gynecol 1999; 180: 114-121.
23. Abbasi S, Hirsch D, Davis J, Tolosa J, Stouffer N, Debbs R, et al. Effect of single versus multiple courses of antenatal corticosteroids on maternal and neonatal outcome. Am J Obstet Gynecol 2000; 182: 1243-1249.
24. Spinillo A, Viazzo F, Colleoni R, Chiara A, Cerbo RA, Fazzi E, et al. Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol 2004; 191: 217-224.
25. Brucato A, Astori MG, Cimaz R, Villa P, Li Destri M, Chimini L, et al. Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to highdose dexamethasone in utero. Ann Rheum Dis 2006; 65: 1422-1426.
26. Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 2005; 38: 55-63.
27. Routsias JG, Tzioufas AG. Sjögren's syndrome: Study of autoantigens and autoantibodies. Clin Rev Allergy Immunol 2007; 32: 238-251.
28. Taylor PV, Taylor KF, Norman A, Griffiths S, Scott JS. Prevalence of maternal Ro (SS-A) and La (SS-B) autoantibodies in relation to congenital heart block. Br J Rheumatol 1988; 27: 128-132.
29. Sonesson SE, Salomonsson S, Jacobsson LA, Bremme K, Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004; 50: 1253-1261.
30. Jaeggi ET, Hamilton RM, Silverman ED, Zamora SA, Hornberger LK. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. J Am Coll Cardiol 2002; 39: 130-137.
31. Maeno Y, Himeno W, Saito A, Hiraishi S, Hirose O, Ikuma M, et al. Clinical course of fetal congenital atrioventricular block in the Japanese population: A multicentre experience. Heart 2005; 91: 1075-1079.
32. Rein AJ, Mevorach D, Perles Z, Gavri S, Nadjari M, Nir A, et al. Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro -SSB/La antibodies: A prospective, observational, fetal kinetocardiogram-based study. Circulation 2009; 119: 1867-1872.
33. Friedman DM, Kim MY, Copel JA, Davis C, Phoon CK, Glickstein JS, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: The PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117: 485-493.
34. Friedman DM, Llanos C, Izmirly PM, Brock B, Byron J, Copel JA, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010; 62: 1138-1146.
35. Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G, et al. Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum 2004; 50: 1248-1252.
36. Ravens U, Cerbai E. Role of potassium currents in cardiac arrhythmias. Europace 2008; 10: 1133-1137.
37. Nakamura K, Katayama Y, Kusano KF, Haraoka K, Tani Y, Nagase S, et al. Anti-KCNH2 antibody-induced long QT syndrome: Novel acquired form of long QT syndrome. J Am Coll Cardiol 2007; 50: 1808-1809.
38. Cuneo BF, Zhao H, Strasburger JF, Ovadia M, Huhta JC, Wakai RT, et al. Atrial and ventricular rate response and patterns of heart rate acceleration during maternal-fetal terbutaline treatment of fetal complete heart block. Am J Cardiol 2007; 100: 661-665.
39. Nishizaki M, Hiraoka M. Gene mutations associated with atrioventricular block complicated by long QT syndrome. Circ J 2010; 74: 2546-2547.
40. Oka Y, Itoh H, Ding WG, Shimizu W, Makiyama T, Ohno S, et al. Atrioventricular block-induced Torsades de Pointes with clinical and molecular backgrounds similar to congenital long QT syndrome. Circ J 2010; 74: 2562-2571.